Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 10, 2009, Pages 1476-1484

  Parmentier Decrucq, Erika ^a,b,c   Duhamel, Alain ^c   Ernst, Olivier ^c   Fermont, Catherine ^c   Louvet, Alexandre ^a,b,c   Vernier Massouille, Gwenola ^a,b,c   Cortot, Antoine ^a,b,c   Colombel, Jean Frédéric ^a,b,c   Desreumaux, Pierre ^a,b,c   Peyrin Biroulet, Laurent ^a  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Abdominal fat; Cholesterol; Crohn's disease; Infliximab; Lipid

Indexed keywords

AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; TRIACYLGLYCEROL;

ABDOMINAL FAT; ABDOMINAL SUBCUTANEOUS FAT; ADULT; ANUS DISEASE; ANUS FISTULA; ARTICLE; BODY MASS; CLINICAL TRIAL; CROHN DISEASE; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ABDOMINAL FAT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; CHOLESTEROL; COLONOSCOPY; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; METABOLOME; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 70350604310     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20931     Document Type: Article

References (59)

1. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374. (Pubitemid 41443403)
2. Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-890.
3. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704-712. (Pubitemid 44244541)
4. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-1356. (Pubitemid 34754607)
5. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644-653. (Pubitemid 351783447)
6. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-756. (Pubitemid 41070815)
7. Ryden M, Dicker A, van Halm V, et al. Mapping of early signaling events in tumor necrosis factor-alpha-mediated lipolysis in human fat cells. J Biol Chem. 2002;277:1085-1091. (Pubitemid 34968854)
8. Popa C, Netea MG, van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48:751-762. (Pubitemid 46557880)
9. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-2180.
10. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91. (Pubitemid 23036092)
11. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254-260.
12. Suzuki R, Watanabe S, Hirai Y, et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med. 1993;95:309-314. (Pubitemid 23270289)
13. Tokunaga K, Matsuzawa Y, Ishikawa K, et al. A novel technique for the determination of body fat by computed tomography. Int J Obes. 1983;7:437-445.
14. Shibasaki M, Takahashi K, Itou T, et al. Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia. 2002;45:518-526.
15. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factoralpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes. 2002;51:1876-1883. (Pubitemid 34564301)
16. Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab. 2005;90:3510-3516. (Pubitemid 41014321)
17. Gentile S, Guarino G, Bizzarro A, et al. Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease. Diabetes Obes Metab. 2002;4:276-277. (Pubitemid 34814869)
18. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut. 2007;56:577-583.
19. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology. 1999;117:73-81. (Pubitemid 29297622)
20. Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2006;10:7-11. (Pubitemid 43299603)
21. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885. (Pubitemid 38252535)
22. Terry JG, Hinson WH, Evans GW, et al. Evaluation of magnetic resonance imaging for quantification of intraabdominal fat in human beings by spin-echo and inversion-recovery protocols. Am J Clin Nutr. 1995;62:297-301.
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
24. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1503-1507. (Pubitemid 350032660)
25. Brown H, Prescott R. Applied mixed models in medicine. New York: John Wiley & Sons; 1999.
26. Bjorntorp P. Adipose tissue distribution and function. Int J Obes. 1991;15(Suppl 2):67-81.
27. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 1996;20:291-302. (Pubitemid 26110403)
28. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32:539-546.
29. Wooten N, Bakalov VK, Hill S, et al. Reduced abdominal adiposity and improved glucose tolerance in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab. 2008;93:2109-2114. (Pubitemid 351831523)
30. Katznelson L, Fairfield WP, Zeizafoun N, et al. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab. 2003;88:5468-5472. (Pubitemid 37452756)
31. Boyd MA, Carr A, Ruxrungtham K, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis. 2006;194:642-650. (Pubitemid 44297850)
32. Good M, Newell FM, Haupt LM, et al. TNF and TNF receptor expression and insulin sensitivity in human omental and subcutaneous adipose tissue - influence of BMI and adipose distribution. Diab Vasc Dis Res. 2006;3:26-33. (Pubitemid 43877250)
33. Bullo M, Garcia-Lorda P, Peinado-Onsurbe J, et al. TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord. 2002;26:652-658. (Pubitemid 34499285)
34. Funt SA, Krinsky G, Horowitz L. Clinical image. MR demonstration of submucosal fat in a patient with Crohn's disease. J Comput Assist Tomogr. 1996;20:940-941. (Pubitemid 26392559)
35. Joyner JM, Hutley LJ, Cameron DP. Glucocorticoid receptors in human preadipocytes: regional and gender differences. J Endocrinol. 2000;166:145-152.
36. Briot K, Gossec L, Kolta S, et al. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2008;35:855-861. (Pubitemid 351747128)
37. Prins JB, Niesler CU, Winterford CM, et al. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997;46:1939-1944. (Pubitemid 27512077)
38. Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta. 2006;365:143-148. (Pubitemid 43196430)
39. Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166:902-908.
40. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti TNFalpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. Wien Klin Wochenschr. 2002;114:1004-1007. (Pubitemid 36105546)
41. Dahlqvist SR, Engstrand S, Berglin E, et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol. 2006;35:107-111.
42. Di Rocco P, Manco M, Rosa G, et al. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res. 2004;12:734-739. (Pubitemid 41132519)
43. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517-525. (Pubitemid 41527607)
44. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Antitumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24:83-86.
45. Irace C, Mancuso G, Fiaschi E, et al. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis. 2004;177:113-118. (Pubitemid 39361145)
46. Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765-766. (Pubitemid 40559306)
47. Kiortsis DN, Mavridis AK, Filippatos TD, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33:921-923.
48. Lo J, Bernstein LE, Canavan B, et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007;293:E102-E109.
49. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis. 2007;66:958-961. (Pubitemid 46999801)
50. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303-305. (Pubitemid 40193632)
51. Seriolo B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci. 2006;1069:414-419. (Pubitemid 43989884)
52. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine. 2008;75:22-24.
53. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33:2440-2446. (Pubitemid 46067823)
54. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26:1495-1498. (Pubitemid 47201685)
55. van Eijk IC, Peters MJ, Nurmohamed MT, et al. Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. Eur J Endocrinol. 2007;156:291-293.
56. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol. 2005;32:252-255. (Pubitemid 40209122)
57. Yazdani-Biuki B, Stelzl H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest. 2004;34:641-642. (Pubitemid 39331479)
58. Sherman ML, Spriggs DR, Arthur KA, et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988;6:344-350.
59. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454. (Pubitemid 29084777)